血清microRNA作为胶质瘤术后监测生物标志物
研究纳入91例胶质瘤患者和17例健康对照,用Nanostring®进行术前和术后血清miRNA分析,通过随机森林机器学习筛选差异表达miRNA,并用微滴数字PCR在11例多次随访患者中验证。结果发现一个9-miRNA特征可将胶质瘤与健康对照区分,准确率99.8%;miR-223和miR-320e的动态变化分别与低级别胶质瘤和胶质母细胞瘤的肿瘤体积密切相关,且在2例假性进展中miRNA水平未升高。
要点
- 9-miRNA特征区分胶质瘤与健康对照的准确率达99.8%。
- miR-223和miR-320e动态变化分别与LGG和GBM肿瘤体积密切相关。
- 2例假性进展中miRNA水平未升高,提示可用于指导治疗决策。
核心结论
- 研究识别出一个与胶质瘤血清相关的高准确度9-miRNA特征。
- 特定miRNA在长期随访中的动态变化与肿瘤体积相关。
- 结果支持开展血清miRNA生物标志物的大型前瞻性验证研究。
研究设计与样本
- 前瞻性收集91例胶质瘤患者和17例健康对照的队列。
- 术前和术后血清miRNA采用Nanostring®进行谱分析。
- 差异表达miRNA通过机器学习随机森林分析发现。
- 候选miRNA在11例多次随访样本中用微滴数字PCR评估,并与基于磁共振成像的肿瘤体积比较。
主要发现
- 一个9基因miRNA特征可区分胶质瘤与健康对照,准确率为99.8%。
- miR-223和miR-320e分别与LGG和GBM的肿瘤体积动态变化密切相关。
- 2例假性进展病例中miRNA水平未升高。
临床怎么用
- 血清miRNA有望用于胶质瘤患者治疗后的纵向监测。
- miRNA水平未升高可能有助于区分假性进展与真性进展,辅助治疗决策。
- 当前结果尚需大型前瞻性验证后才能进入临床常规。
局限性
- 候选miRNA仅在11例多次随访患者中验证。
- 假性进展仅在2例病例中观察。
- 研究结论明确指出尚需大型前瞻性验证研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A circulating biomarker has potential to provide more accurate information for glioma progression post treatment, however no such biomarker is currently available. We aimed to discover a microRNA serum biomarker for longitudinal monitoring of glioma patients. METHODS: A prospectively collected cohort of 91 glioma patients and 17 healthy controls underwent pre and post-operative serum miRNA profiling using Nanostring®. Differentially expressed miRNAs were discovered using a machine learning random forest analysis. Candidate miRNAs were then assessed by droplet digital PCR in 11 patients with multiple follow up samples and compared to tumor volume based on magnetic resonance imaging. RESULTS: A 9-gene miRNA signature was identified that could distinguish between glioma and healthy controls with 99.8% accuracy. Two miRNAs miR-223 and miR-320e, best demonstrated dynamic changes that correlated closely with tumor volume in LGG and GBM respectively. Importantly, miRNA levels did not increase in two cases of pseudo-progression, indicating the potential utility of this test in guiding treatment decisions. CONCLUSIONS: We identified a highly accurate 9-miRNA signature associated with glioma serum. Additionally, we observed dynamic changes in specific miRNAs correlating with tumor volume over long-term follow up. These results support a large prospective validation study of serum miRNA biomarkers in glioma.
引用
- Morokoff A, Jones J, Nguyen H, et al. Serum microRNA is a biomarker for post-operative monitoring in glioma. J Neurooncol. 2020. PMID: 32915353. doi:10.1007/s11060-020-03566-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。